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11 Abstract Multiple sclerosis (MS) pathology is characterized
12 by neuroinflammation and demyelination. Recently, the in-
13 flammatory molecule S100B was identified in cerebrospinal
14 fluid (CSF) and serum of MS patients. Although seen as an
15 astrogliosis marker, lower/physiological levels of S100B are
16 involved in oligodendrocyte differentiation/maturation. Nev-
17 ertheless, increased S100B levels released upon injury may
18 induce glial reactivity and oligodendrocyte demise, exacerbat-
19 ing tissue damage during an MS episode or delaying the fol-
20 lowing remyelination. Here, we aimed to unravel the function-
21 al role of S100B in the pathogenesis of MS. Elevated S100B
22 levels were detected in the CSF of relapsing-remitting MS
23 patients at diagnosis. Active demyelinating MS lesions
24 showed increased expression of S100B and its receptor, the
25receptor for advanced glycation end products (RAGE), in the
26lesion area, while chronic active lesions displayed increased
27S100B in demyelinated areas with lower expression of RAGE
28in the rim. Interestingly, reactive astrocytes were identified as
29the predominant cellular source of S100B, whereas RAGE
30was expressed by activated microglia/macrophages. Using
31an ex vivo demyelinating model, cerebral organotypic slice
32cultures treated with lysophosphatidylcholine (LPC), we ob-
33served a marked elevation of S100B upon demyelination,
34which co-localized mostly with astrocytes. Inhibition of
35S100B action using a directed antibody reduced LPC-
36induced demyelination, prevented astrocyte reactivity and ab-
37rogated the expression of inflammatory and inflammasome-
38related molecules. Overall, high S100B expression in MS pa-
39tient samples suggests its usefulness as a diagnostic biomarker
40for MS, while the beneficial outcome of its inhibition in our
41demyelinating model indicates S100B as an emerging thera-
42peutic target in MS.
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46Introduction
47Multiple sclerosis (MS) is a primary inflammatory demyelin-
48ating autoimmune disorder of the central nervous system
49(CNS) affecting mainly young people aged between 20 and
5040 years at disease onset. In early stages of the disease MS, it
51is characterized by infiltration and activation of T cells and
52accumulation of monocyte-derived macrophages, which pro-
53mote destruction of the myelin sheath leading to the formation
54of focal demyelinated lesions [1].
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55 Diagnosis and follow-up in MS are usually based on as-
56 sessment of clinical symptoms, in particular the presentation
57 of relapses, and supported by magnetic resonance imaging
58 (MRI). A disadvantage of MRI is its lack of specificity for a
59 particular MS hallmark, as the detected lesions can be due to
60 oedema, inflammation, gliosis, demyelination or axonal loss.
61 In addition, current medical treatment aimed at delaying dis-
62 ease progression mainly targets the immune system. In this
63 context, it is important to identify novel biomarkers for MS
64 diagnosis and progression, as well as new therapeutic targets
65 to reduce damage and improve disease recovery.
66 S100B is a small Ca2+-binding protein member of the S100
67 family, which is mostly expressed by astrocytes, a small sub-
68 set of oligodendrocytes (OLs) and certain neuronal subpopu-
69 lations [2, 3]. S100B exerts both intracellular and extracellular
70 functions. Intracellularly, S100B acts as a signalling molecule,
71 promoting neuronal proliferation, OL differentiation and as-
72 sembly of cytoskeleton components important for maintaining
73 astrocyte morphology, while facilitating astrocyte and microg-
74 lia migration [4]. Interestingly, regarding extracellular func-
75 tions, S100B can either act as a neurotrophic or neurotoxic
76 molecule, depending on the concentration attained. At low
77 and physiological concentrations (nanomolar), S100B is
78 thought to promote neurite extension and neuronal survival
79 during development, enhance astrocytic proliferation, and fa-
80 vour microglia chemotactic ability and quiescence [5–8].
81 Under stress conditions, namely, traumatic brain injury [9]
82 or CNS infection [10], S100B reaches concentrations in the
83 micromolar range and exerts neurotoxic effects [11]. These
84 effects include microglial and astrocyte activation, with re-
85 lease of inflammatory and oxidative stress mediators [12],
86 which contribute to neuronal death [12, 13]. Both trophic
87 and toxic effects of extracellular S100B are mediated in the
88 brain by its binding to the receptor for advanced glycation end
89 products (RAGE) [14].
90 Augmented S100B levels were first detected in cerebrospi-
91 nal fluid (CSF) of MS patients in the acute phase [15]. More
92 recently, Petzold and collaborators showed the presence of
93 S100B in acute lesions of post-mortem brain tissue of MS
94 patients with relapsing-remitting multiple sclerosis (RRMS)
95 [16], while it was shown to be increased in CSF [17] or serum
96 of MS patients, decreasing after immunosuppressive [18] or
97 natalizumab [19] therapies. However, no further studies clar-
98 ified the role of S100B and its receptor RAGE in different
99 stages of MS lesions or on disease progression.
100 So, here, we aimed to evaluate the contribution of S100B
101 as a biomarker of MS diagnosis and as a determinant of de-
102 myelination or delayed remyelination. Our findings in human
103 CSF samples from RRMS patients showed a significant in-
104 crease of S100B production at the time of diagnosis that was
105 corroborated by a slight S100B increase in respective serum
106 samples. Moreover, we showed that S100B is highly upregu-
107 lated in active and chronic active MS lesions mainly in
108astrocytes. Enhanced expression of S100B receptor RAGE
109was predominantly observed in macrophages/microglia in ac-
110tive lesions. Using an ex vivo demyelinating model, we dem-
111onstrate that S100B is highly expressed and released upon
112demyelination, in parallel with activation of astrocytes and
113microglia as well as upregulation of pro-inflammatory cyto-
114kine and inflammasome-related gene expression. Interesting-
115ly, neutralization of extracellular S100B prevented demyelin-
116ation, decreased reactive gliosis and abrogated expression of
117key pro-inflammatory factors. Overall, our data demonstrate
118that S100B expression is altered in MS patients, in that the
119protein is involved in demyelination mechanisms and is cru-
120cial for the inflammatory milieu, which can be important for
121the design of new therapeutic strategies to reduce damage or
122promote tissue repair following MS episodes.
123Material and Methods
124CSF and Serum Samples
125Patients with RRMS (all fulfilling revised McDonald 2005
126criteria) were recruited at Hospital de Braga. The study was
127approved by the local ethics committee (CESHB) and the na-
128tional authority for data protection (CNPD), and all participants
129gave written informed consent before inclusion. In this study, we
130included 11 patients at the time of diagnosis of RRMS and 11
131controls (non-inflammatory/inflammatory neurological disor-
132ders). Detailed clinical data ofMS patients and controls are sum-
133marized in Table 1. Between 3 and 5 mL of CSF was collected
134by lumbar puncture, and the first 2 mL was discarded/used for
135clinical purposes, while the remaining was kept refrigerated until
136aliquoted and stored at −80 °C within 2 h of collection. Blood
137was also collected at the time of lumbar punctures, from a
t1:1Table 1 Clinical data of patients with relapsing-remitting multiple
sclerosis (RRMS) and non-inflammatory/inflammatory neurological
disorder (NA) controls
t1:2Case Age Sex Case Age Sex
t1:3NA 13 57 M RRMS 21 55 M
t1:4NA18 25 M RRMS 33 22 F
t1:5NA25 38 F RRMS 60 21 F
t1:6NA31 39 M RRMS 61 26 M
t1:7NA36 44 M RRMS 80 47 M
t1:8NA58 59 F RRMS 82 27 F
t1:9NA63 74 M RRMS 92 39 M
t1:10NA65 84 F RRMS 104 25 F
t1:11NA69 20 F RRMS 107 48 F
t1:12NA78 30 M RRMS 109 38 F
t1:13NA105 69 F RRMS 114 23 M
M male, F female
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138 peripheral vein directly to serum tubes (4 mL). After clotting at
139 room temperature, the serum supernatant was also aliquoted
140 (within 2 h of collection) and stored at −80 °C until further use.
141 S100B Determination
142 Determination of S100B concentration was performed by in-
143 house enzyme-linked immunosorbent assay (ELISA) as usual
144 in our laboratory [20]. Briefly, CSF and serum samples were
145 incubated for 2 h at 37 °C on a 96-well plate previously coated
146 with a monoclonal anti-S100B antibody (1:1000, Sigma-Al-
147 drich, St. Louis, MO, USA). Thereafter, a polyclonal anti-
148 S100B antibody (1:5000, DAKO, Glostrup, Denmark) was
149 added and samples additionally incubated for 30 min at
150 37 °C. Finally, an anti-rabbit peroxidase-conjugated antibody
151 (1:5000, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
152 was added for further 30 min at 37 °C. The colorimetric reac-
153 tion with Sigma Fast OPD tablets® (Sigma-Aldrich) was mea-
154 sured at 492 nm in amicroplate absorbance spectrophotometer.
155 Brain Tissue
156 Brain tissue was obtained in collaboration with the Depart-
157 ment of Pathology, VU University Medical Center Amster-
158 dam and the Netherlands Brain Bank, Amsterdam, the Neth-
159 erlands. For immunohistochemical analysis, we selected brain
160 samples from nineMS patients and two non-neurological con-
161 trols, which were carefully matched for age, sex, and port-
162 mortem delay. The Netherlands Brain Bank received permis-
163 sion to perform autopsies for the use of tissue and for access to
164 medical records for research purposes from the ethics commit-
165 tee of the VU Medical Center (Amsterdam, the Netherlands).
166 Tissue samples from control cases were taken from the sub-
167 cortical white matter or corpus callosum. MS tissue samples
168 were selected on the basis of post-mortem MRI and lesions
169 were classified according to standard histopathological criteria
170 as previously published [21]. Based on this classification, six
171 active and six chronic active lesions were identified. Detailed
172 clinical data of MS patients and controls are summarized in
173 Table 2. Immediately after excision, tissue was fixed in form-
174 aldehyde and snap-frozen in liquid nitrogen for immunohisto-
175 chemistry. The study was approved by the institutional ethics
176 review board (VU University Medical Center, Amsterdam,
177 the Netherlands), and all donors or their next of kin provided
178 written informed consent from brain autopsy, use of material
179 and clinical information for research purposes.
180 Immunohistochemistry
181 Frozen sections were stained as previously described [22, 23].
182 In short, 5-μm-thick cryosections were collected on
183 Superfrost Plus glass slides, defrosted at room temperature
184 and fixed in acetone for 10 min. After fixation and blocking
185[1 % bovine serum albumin (BSA), 0.05 % Tween-20 and
18610 % goat serum in phosphate-buffered saline solution
187(PBS)], sections were incubated with primary antibodies for
1881 h at room temperature. The following antibodies were used:
189proteolipid protein (PLP; 1:3000, Serotec, Raleigh, NC, USA)
190for myelin, HLA-DR major histocompatibility complex
191(MHC-II) clone LN3 (LN3; 1:1000) for macrophages/microg-
192lia, S100B (1:7000, Abcam, Cambridge, UK) and RAGE
193(1:200, Abcam). Detection was performed with EnVision
194Kit rabbit/mouse-labelled horseradish peroxidase (DAKO)
195for 30 min at room temperature. After a short rinse in tap
196water, sections were counterstained with haematoxylin for
1971 min and extensively washed with tap water for 5 min. Fi-
198nally, sections were dehydrated within a series of ethanol and
199xylene baths and mounted with Entellan (Merck Millipore,
200Darmstadt, Germany). Images were taken on a Leica
201DM4000B microscope (Leica Microsystems Heidelberg
202GmbH, Mannheim, Germany).
203Immunofluorescence
204To reveal the cellular localization of S100B and RAGE, im-
205munofluorescent double labelling was performed as described
206before [23]. Sections were incubated for 30 min in PBS con-
207taining 1 % BSA, 0.05 % Tween-20 and 10 % normal goat
208serum. The sections were then incubated with glial fibrillary
209acidic protein (GFAP; 1:2000, Chemicon, Temecula, CA,
210USA) and S100B (1:3500) or LN3 (1:500) and RAGE
211(1:100) overnight at 4 °C. The next day, sections were incu-
212bated with secondary antibodies for 1 h at room temperature.
213To reduce autofluorescence, sections were counterstainedwith
214Sudan Black (0.3 % in ethanol 70%; Sigma). Finally, sections
t2:1Table 2 Clinical data of patients with multiple sclerosis (MS) and non-
neurological controls
t2:2Case Age Type
of MS
Gender Post-mortem
delay (h:min)
Disease duration
(years)
t2:3MS1 66 SP F 6 22
t2:4MS2 61 SP M 9:15 31
t2:5MS3 41 PP M 7:23 14
t2:6MS4 49 SP M 8 25
t2:7MS5 76 PP M 7:30 26
t2:8MS6 51 SP M 11 >10
t2:9MS7 44 ND M 10:10 21
t2:10MS8 47 ND F 4:25 21
t2:11MS9 44 ND M 12 16
t2:12Ctrl1 84 NA F 6:55 NA
t2:13Ctrl2 56 NA M 9:15 NA
SP secondary progressive MS, PP primary progressive MS, ND not de-
termined, M male, F female
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215 were stained with Hoechst (1:1000; Molecular Probes,
216 Invitrogen, Carlsbad, CA, USA) to visualize nuclei and
217 mounted with mountingmedium (DAKO). Images were taken
218 on a Leica DM6000 microscope (Leica Microsystems Heidel-
219 berg GmbH).
220 Ex vivo model of demyelination
221 To study the role of S100B during a demyelinating event, we
222 used cerebellar organotypic slice cultures treated with
223 lysophosphatidylcholine (LPC) as previously described [24].
224 Parasagittal slices were obtained from cerebellum of CD1
225 mouse pups at post-natal day 10. Briefly, brains were re-
226 moved, cerebellum and attached hindbrain were isolated in
227 PBS, and 400-μm slices were obtained using a McIlwain tis-
228 sue chopper and kept in an air-liquid interface system. Sepa-
229 rated slices were placed in the upper chamber of a 0.4-μm
230 pore cell culture (BD Falcon, Lincoln Park, NJ, USA) in a
231 number of four slices per insert. Cell culture inserts were
232 maintained in six-well cell culture plates containing 1 mL of
233 medium in the plate well at a 37 °C and 5 % CO2 conditioned
234 atmosphere. Slice culture media consisted of 50 % minimal
235 essential media (MEM, Gibco, Life Technologies, Inc., Grand
236 Island, USA), 25 % heat-inactivated horse serum (Gibco),
237 25 % Earl’s balanced salt solution (Gibco), 6.5 mg/mL glu-
238 cose, 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
239 acid (HEPES) (Biochrom AG, Berlin, Germany), and 1 % of
240 both L-glutamine (Sigma-Aldrich) and penicill in/
241 streptomycin (Sigma-Aldrich). After 3 days in vitro (DIV),
242 slice culture media were totally replaced by a serum-free me-
243 dium consisting of 98 % Neurobasal-A (Gibco) and 2 % B-27
244 (Gibco), supplemented with 2 mM L-glutamine, 36 mM glu-
245 cose, 1% U/mL penicillin/streptomycin and 25 mM HEPES.
246 Half media were replaced every day and slices were main-
247 tained for 7 DIV before treatment, to allow myelination and
248 the clearance of debris. Following 7 DIV, slices were exposed
249 to a demyelinating insult with LPC (0.5 mg/mL in serum-free
250 culture media). Following 18-h treatment with LPC, slices
251 were transferred to serum-free media in which cultures were
252 maintained up to 48 h [24, 25].
253 In parallel experiments, to ascertain S100B role on demy-
254 elination and glial reactivity, slices were incubated with LPC
255 in the presence or absence of anti-S100B antibody (1:1000,
256 Abcam). Additionally, slices were also treated with a non-
257 specific antibody, a goat anti-rabbit secondary antibody, in
258 the presence of LPC to confirm whether the presence of an
259 isotype would change LPC-induced response. Supernatants
260 were collected before and after LPC treatment. Slices were
261 collected at 9 DIV (48 h post-LPC) and either stored in
262 TRIzol® reagent at −20 °C for RNA extraction or fixed in
263 4 % paraformaldehyde in PBS for 1 h, rinsed in PBS and
264 stored in PBS at 4 °C for immunohistochemistry assays.
265Semi-quantitative RT-PCR
266Total RNA was extracted from 9-DIV slices using the
267TRIzol® reagent (Invitrogen) method, according to the man-
268ufacturer’s instructions. RNA concentration was quantified
269using NanoDrop ND-100 Spectrophotometer (NanoDrop
270Technologies, Wilmington, DE, USA). Aliquots of 500 ng
271of total RNA were reversely transcribed into complementary
272DNA (cDNA) using the RivertAid H Minus First Strand
273cDNA Synthesis Kit (Thermo Fisher Scientific, MA, USA),
274under the recommended conditions. Quantitative RT-PCR
275(qRT-PCR) was performed using β-actin as an endogenous
276control to normalize the expression level of S100B, myelin
277basic protein (MBP), PLP and first-line cytokines: tumour
278necrosis factor (TNF)-α; interleukin (IL)-1 and IL-6; and
279inflammasome-related molecules IL-18, high-mobility group
280box protein 1 (HMGB1) and NLRP3. The sequences used as
281primers are listed in the Table 3. qRT-PCRwas performed on a
282real-time PCR detection (Applied Biosystems 7300 Fast Real-
283Time PCR System, Applied Biosystems, Madrid, Spain)
284using an SYBR Green qPCR Master Mix (Thermo Fisher
285Scientific). The PCR was performed in eight-well strips with
286each sample performed in duplicate, and a no-template control
287was included for each amplification product. qRT-PCR was
288performed under optimized conditions: 50 °C for 2 min, 95 °C
289for 10 min followed by 40 cycles at 95 °C for 15 s and 62 °C
290for 1 min. To verify the specificity of the amplification, a melt-
291curve analysis was performed, immediately after the amplifi-
292cation protocol (95 °C for 15 s, followed by 60 °C for 30 s and
29395 °C for 15 s). Non-specific products of PCR were not de-
294tected in any case. Relative messenger RNA (mRNA) concen-
295trations were calculated using the Pfaffl modification of the
296ΔΔCT equation [cycle number at which fluorescence passes
297the threshold level of detection (CT)], taking into account the
298efficiency values of individual genes. The results were nor-
299malized to the housekeeping gene β-actin in the same sample
300and the initial amount of the template of each trial was deter-
301mined as relative expression by the formula 2−ΔΔCT. ΔCT is
302the value obtained, for each sample, by performing the differ-
303ence between the mean CT value of each gene of interest and
304the mean CT value of β-actin. ΔΔCT of one sample is the
305difference between its ΔCT value and the ΔCT of the sample
306chosen as reference.
307Immunostaining Procedure
308After fixation, membranes containing tissue sections were cut
309from cell culture insert and incubated with blocking solution
310(1 nM HEPES, 2 % heat-inactivated horse serum, 10 % heat-
311inactivated goat serum, 1 % BSA and 0.25 % Triton X-100 in
312Hank’s balanced salt solution) for 3 h at room temperature.
313The sections were then incubated with primary antibodies
314diluted in blocking solution for 24 h at 4 °C. The following
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315 antibodies were used: neurofilament medium (NF-200, 1:200,
316 Novocastra, Wetzlar, Germany) for neuronal axons, NG2
317 (1:50, Merck Millipore) for oligodendrocyte precursor cells
318 (OPC), MBP (1:50, Serotec) for mature OLs, GFAP (1:100,
319 Novocastra) for astrocytes, ionized calcium-binding adapter
320 molecule 1 (Iba-1, 1:250, WAKO) for microglia and S100B
321 (1:500, Abcam). Then, slices were washed for three times for
322 15 min each with PBS with 0.01 % Triton X-100 (PBS-T)
323 before incubation for another 24 h at 4 °C with secondary
324 antibody in blocking solution. Slices were washed for three
325 times for 15min eachwith PBS-T, incubated 3minwithDAPI
326 (1:1000), washed for three times for 15 min each with PBS-T
327 and mounted using Fluoromount-G (Southern Biotech, Bir-
328 mingham, AL, USA) for confocal microscopy. The percent-
329 age of the area immunoreactive for each antibody was mea-
330 sured in images captured using a ×20/1.2 (zoom) lens on a
331 Confocal Point Scanning Microscope Zeiss LSM 510 META
332 (Zeiss, Germany). Binary masks were defined using a cut-off
333 intensity threshold value for each region of interest, which
334 corresponds to a minimum intensity due to specific staining
335 above background values. Then, the percentage of the area
336 occupied by NF-200, MBP, GFAP, Iba-1 and S100B was
337 measured automatically using ImageJ software in each cere-
338 bellum region. Regarding myelination, the percentage of my-
339 elinated fibres was obtained by the ratio between the area of
340 co-localization of NF-200 and MBP and the total area occu-
341 pied by NF-200. Results are given by averaging values deter-
342 mined in the separate microscopic fields from slices of differ-
343 ent animals.
344 Statistical Analysis
345 All results are presented as mean±SEM. The difference be-
346 tween control and RRMS patient samples was determined by
347 the Mann-Whitney test, while differences in slice cultures
348 were analyzed by the two-tailed t test performed on the basis
349 of equal and unequal variance or by one-way ANOVA with
350Tukey post-test, using GraphPad PRISM 5.0 (GraphPad Soft-
351ware, San Diego, CA, USA), as appropriate. The P values of
352P<0.05 and P<0.01 were considered as being statistically
353significant.
354Results
355S100B Levels in the CSF and Serum of RRMS Patients
356Are Increased at the Time of Diagnosis
357We first assessed S100B levels in CSF and serum samples of
358RRMS patients (n=13) at the time of diagnosis and controls
359(n=13) by ELISA. As depicted in Fig. 1, S100B concentra-
360tions were markedly increased in the CSF of MS patients at
361time of diagnosis of RRMS when compared with controls
362(1.66 vs. 0.77 ng/L, P<0.01). Although in a smaller magni-
363tude, S100B levels were also elevated in the serum of the same
364patients (1.51 vs. 1.25 ng/L, P<0.05), which corroborates
365previous findings [16, 18], showing that S100B may be a
366potential diagnosis biomarker of MS.
367S100B and RAGE Expression in Human Control Brain
368and Normal-Appearing White Matter
369S100B is known to be increased in homogenates of MS le-
370sions [16]; however, the cellular source of S100B is unknown.
371Hence, we decided to evaluate S100B and its receptor RAGE
372expression in brain samples of MS patients and controls.
373S100B was barely detectable in normal-appearing white mat-
374ter (NAWM), while RAGE immunoreactivity was predomi-
375nantly localized to nuclei of glial cells (Supplementary Fig. 1).
376No differences were observed comparing the expression of
377S100B and RAGE in NAWM with control white matter sam-
378ples (data not shown).
t3:1 Table 3 List of pairs of primers
used for qRT-PCR assayst3:2 Gene Sense Anti-sense
t3:3 S100B GAGAGAGGGTGACAAGCACAA GGCCATAAACTCCTGGAAGTC
t3:4 MBP CCATCCAAGAAGACCCCACA CCCCTGTCACCGCTAAAGAA
t3:5 PLP TGGCGACTACAAGACCACCA GACACACCCGCTCCAAAGAA
t3:6 TNF-α TACTGAACTTCGGGGTGATTGGTCC CAGCCTTGTCCCTTGAAGAGAACC
t3:7 IL-1β CAGGCTCCGAGATGAACAAC GGTGGAGAGCTTTCAGCTCATA
t3:8 IL-6 CCGGAGAGGAGACTTCACAG GGAAATTGGGGTAGGAAGGA
t3:9 IL-18 TGGTTCCATGCTTTCTGGACTCCT TTCCTGGGCCAAGAGGAAGTG
t3:10 HMGB1 CTCAGAGAGGTGGAAGACCATGT GGGATGTAGGTTTTCATTTCTCTTTC
t3:11 NRLP3 TGCTCTTCACTGCTATCAAGCCCT ACAAGCCTTTGCTCCAGACCCTAT
t3:12 β-Actin GCTCCGGCATGTGCAA AGGATCTTCATGAGGTAGT
All primers were purchased from Thermo Fisher Scientific, MA, USA
HMGB1 high-mobility group box protein 1, IL interleukin, TNF tumour necrosis factor
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379 S100B and RAGE Expression in MS Lesions
380 Active demyelinating MS lesions are characterized by loss of
381 myelin and abundant PLP-positive macrophages. S100B ex-
382 pression was markedly increased in demyelinated white mat-
383 ter regions (Fig. 2a) and localized to cell bodies and processes
384 of reactive astrocyte-like cells (Fig. 2b). Astroglial source of
385 S100B was further confirmed with double immunofluores-
386 cence labelling for S100B (green) and an astrocytic marker,
387 GFAP (red) (inset in Fig. 2b—S100B). RAGE expression was
388 also strikingly increased in active white matter lesions
389 (Fig. 2a) and mainly localized to macrophages and activated
390 microglia (Fig. 2b), which was confirmed by double immu-
391 nofluorescence labelling for RAGE (green) and LN3 (red)
392 (inset in Fig 2b—RAGE).
393 Analysis of chronic active MS lesions is characterized by a
394 demyelinated lesion centre devoid of immune cells and a rim
395 of activated microglia and macrophages. S100B expression
396 was increased throughout the demyelinated areas (Fig. 3a).
397 S100B diffuse staining resembles the morphology of astrocyte
398 processes that constitute the gliotic scar tissue in the lesion
399 centre (Fig. 3b). Conversely, RAGE was weakly expressed
400by a few cells in the rim but virtually absent in the inactive
401hypocellular centre (Fig. 3a, b).
402Ex vivo Demyelinating Model Shows a Marked
403Overexpression and Release of S100B Following
404the Demyelination Insult
405As we observed abnormal levels of S100B in CSF and serum
406of MS patients and in MS lesion samples, we decided to ex-
407plore whether S100B was differentially expressed and
Fig. 1 S100B elevated levels detected in cerebrospinal fluid and serum
of multiple sclerosis (MS) patients at time of diagnosis of relapsing-
remitting MS (RRMS) form. S100B was determined by ELISA in
cerebrospinal fluid (a) and serum (b) of MS patients collected at time of
diagnosis and of controls. Results are mean±SEM from eight samples
performed in duplicate. TheMain-Whitney test was used to determine the
statistical significance (**P<0.01 and *P<0.05vs. controls)
Fig. 2 S100B and its receptor, the receptor for advanced glycation end
products (RAGE), are markedly expressed in active multiple sclerosis
(MS) lesions by astrocytes and macrophages/microglial cells,
respectively. Sequential frozen sections of autopsied brain samples of
MS patients were immunostained for proteolipid protein (PLP) to detect
white matter and for HLA-DR MHC class II clone LN3 to detect
macrophages/microglial cells, as well as for S100B and RAGE. a
S100B and RAGE expression is increased within active MS lesions,
outlined by PLP staining and LN3 immunoreactivity. Magnification
×10. b S100-positive cells have morphological characteristics of
astrocytes and RAGE-positive cells of activated macrophages/
microglia. Magnification ×40. Insets show the co-localization of (I)
glial fibrillary acidic protein (GFAP, red), an astrocytic marker, with
S100B (green) and the co-localization of (II) LN3 (red), a marker of
activated microglia/macrophages with RAGE (green). Magnification ×63
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408 secreted upon a demyelinating event. First, we examined if
409 S100B was being expressed in our model of demyelination.
410 In this context, the levels of S100B protein released to the
411 extracellular space were quantified in slices or incubation me-
412 dia collected before the demyelination with LPC (0 h), imme-
413 diately after the LPC stimulus of 18 h, and at 48 h, i.e. after
414 30 h of recovery, by ELISA. As shown in Fig. 4a, a striking
415 increase in the release of S100B occurred upon 18 h of LPC
416 incubation (20.8-fold vs. control, P<0.001), which was main-
417 tained at 48 h (12.3-fold vs. control, P<0.001). In addition,
418 determination of S100B mRNA expression in the slices at
419 48 h, by qRT-PCR, revealed that it was a significant increase
420 of S100B expression (3.51-fold vs. control, P<0.01) even
421 after 30 h of recovery post-LPC treatment, thus suggesting
422that S100B is continuously induced by events resulting from
423the demyelinating insult (Fig. 4b).
424S100B Is Mainly Released by Astrocytes Following LPC
425Demyelination
426Knowing that S100B is mainly expressed by astrocytes in ac-
427tive MS lesions and that it is overexpressed and released to the
428extracellular space in our ex vivo demyelinating model, we
429further assessed the cellular origin of S100B in our experimen-
430tal model. For this end, we performed double immunofluores-
431cence to determine the cellular localization of S100B. Here,
432slices were double immunostained with antibodies against
433S100B and specific cellular markers (NF-200, GFAP or
434MBP). As shown in Fig. 5, S100B clearly co-localized with
435GFAP-positive astrocytes in control samples. Upon LPC treat-
436ment, co-localization of S100B with GFAP is the most preva-
437lent, although we could observe some co-localization of S100B
438with MBP-positive structures. These findings corroborate the
Fig. 3 S100B but not the receptor for advanced glycation end products
(RAGE) is continuously expressed in chronic multiple sclerosis (MS)
lesions. Sequential frozen sections of autopsied brain samples of MS
patients were immunostained for proteolipid protein (PLP) to detect
white matter and HLA-DR MHC class II clone LN3 to identify
macrophages/microglial cells, as well as for S100B and RAGE. a
S100B is increased within the inactive centre of MS lesions and a weak
RAGE expression is confined to the rim. Magnification ×10. bWithin the
lesion, S100B-positive cells have morphological characteristics of
astrocytes, while only a few RAGE-positive cells are observed within
the rim of the lesion. Magnification × 40
Fig. 4 Demyelination induces a massive release and continuous
overexpression of S100B in cerebellar organotypic slice cultures.
Ce rebe l l a r o rgano typ ic s l i ce cu l tu re s were exposed to
lysophosphatidylcholine (LPC) at 7 days in vitro (0 h) for 18 h. a
Samples for detection of S100B secretion were collected before the
incubation (0 h), at 18 h post-incubation with LPC and at 48 h, i.e. after
30 h of recovery. b Samples for analysis of mRNA expression were
collected at 48 h. Results are mean±SEM from at least eight
independent experiments. One-way ANOVA with Tukey post-test or t
test was used to determine the statistical significance as appropriate
(**P<0.01 and ***P<0.001 vs. control)
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439 MS lesion data, indicating that astrocytes are the major pro-
440 ducers of S100B under demyelinating circumstances.
441 Neutralization of S100B Prevents LPC-Induced
442 Demyelination
443 Knowing that S100B is being overly secreted in response to
444 LPC-induced demyelination, we wanted to understand whether
445 the increase in extracellular S100B could be involved in the
446 demyelination process. First, we measure the amount of NF-
447 200-positive axons to assure that LPC treatment was only af-
448 fecting oligodendrocytes/myelin without axonal loss. As shown
449 in Fig. 6a, b, the amount of NF-200 did not change following
450 LPC incubation corroborating a specific oligodendrocyte/
451 myelin toxicity. Next, we evaluated the percentage of myelin-
452 ated fibres in slices after recovery, which was calculated by the
453 ratio of the area of co-localization of NF-200 and MBP and the
454 area occupied by NF-200 alone. As depicted in Fig. 6a, c, LPC
455 stimulus effectively damaged myelin sheaths, which was cor-
456 roborated by the decrease observed in the percentage of mye-
457 linated fibres (0.60-fold, P<0.01). Interestingly, co-incubation
458 with anti-S100B antibody prevented the demyelination caused
459 by LPC in 55% (P<0.01). To assure that the use of an antibody
460 did not have any role on the prevention of demyelination, we
461 also evaluated the gene expression of MBP and PLP in cultures
462 treated with a non-specific IgG plus LPC in parallel with the
463 presented incubation scheme. As shown in Supplementary
464 Fig. 2, LPC incubation markedly affected MBP and PLP
465mRNA expression (0.61-fold, P<0.01, and 0.70-fold,
466P<0.05, respectively) that was partially prevented by S100B
467neutralization (59 %, P<0.05, and 37 %, respectively). Co-
468incubation of LPC with IgG did not change MBP and PLP
469mRNA expression corroborating that the presence of an isotype
470does not alter LPC-induced response. These findings indicate
471that S100B plays a role in LPC-dependent demyelination of
472cerebellar organotypic slice cultures.
473Abrogation of S100B Decreases Astroglial Reactivity
474Induced by demyelination
475Along with myelin degeneration, demyelinating lesions are
476also characterized by astrocytosis and microgliosis [26, 27].
477Regarding this issue and knowing that S100B is mainly se-
478creted by astrocytes and is involved in the activation of both
479astrocytes and microglia, we decided to evaluate the degree of
480reactive gliosis in the course of the demyelinating insult with
481LPC (Figs. 7 and 8). LPC-treated slices evaluated at 48 h
482showed a marked decrease in the percentage of area occupied
483by astrocytes (0.4-fold vs. control, P<0.01), as a consequence
484of reduced extension and number of cellular processes in ac-
485tivated cells (Fig. 7). Interestingly, when slices were co-
486incubated with the neutralizing S100B antibody, astrocytes
487retained their more ramified morphology as seen in control
488slices, increasing the percentage of the area occupied by as-
489trocytes (1.2-fold vs. control), thus suggesting a reduced acti-
490vated state.
Fig. 5 S100B is mainly
expressed by astrocytes both in
control cultures and upon
demyelination. Cerebellar
organotypic slice cultures were
exposed to
lysophosphatidylcholine (LPC) at
7 days in vitro (0 h) for 18 h.
Immunostainings were performed
in slices fixed at 48 h for S100B,
neurons (neurofilament-200 (NF-
200)), astrocytes (glial fibrillary
acidic protein (GFAP)) and
oligodendrocytes (myelin basic
protein (MBP)). S100B
expression mainly co-localizes
with GFAP-positive astrocytes
both in control and in LPC
treatment. Representative images
of at least eight independent
experiments are shown. Scale bar
represents 100 μm
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491 Regarding microglia, as shown in Fig. 8, incubation with
492 LPC markedly increased the area occupied by Iba-1-positive
493 microglia (2.0-fold vs. control, P<0.01), suggesting an in-
494 crease of microglial number, and changed their morphology
495 to a more amoeboid/activated state. Co-incubation with anti-
496 S100B antibody in the presence of LPC did not attenuate
497 microglial proliferation/activation induced by LPC-mediated
498 demyelination.
499 Neutralization of S100B Prevents LPC-Induced Gene
500 Expression of First-Line Cytokines
501 and Inflammasome-Associated Components
502 Along with astrocytic and microglial activation, demyelin-
503 ation is accompanied by exacerbated production of pro-
504 inflammatory cytokines and an increased production of
505 inflammasome-related proteins [19, 28]. This inflammatory
506 milieu is crucial for determination of lesion extent, immune
507 cell recruitment and ability to remyelinate. Curiously, S100B
508 was reported to promote microglial and astroglial release of
509 IL-1β and TNF-α when present in elevated concentrations
510 [12], as we have observed here in our demyelinating model.
511So, we then evaluated gene expression of these inflammatory
512mediators upon demyelination and in the presence of anti-
513S100B antibody. As depicted in Fig. 9, there is still a marked
514increase in the expression of first-line cytokines TNF-α (2.2-
515fold vs. control, P<0.01) and IL-1β (6.8-fold vs. control,
516P<0.01) and a reduction of IL-6 (0.3-fold vs. control,
517P<0.01), during the recovery period after LPC insult. Inter-
518estingly, when slices exposed to LPC were co-incubated with
519anti-S100B antibody, the expression of both TNF-α and IL-
5201β remained similar to control values (P<0.01), while IL-6
521inhibition was prevented by ~50 % (P<0.01). These results
522corroborate the induction of a marked inflammatory response
523upon demyelination induction and suggest that S100B is in-
524volved in cytokine release by glial cells.
525Inflammasomes are cytosolic protein complexes involved in
526the maturation and secretion of pro-inflammatory mediators
527including IL-1β, IL-18 and HMGB1 [28, 29]. More recently,
528inflammasomes, namely, the NLRP3 inflammasome, have
529been associated with MS development [28]. Since we have
530observed such a marked LPC-induced increase of IL-1β and
531protection in the presence of anti-S100B, we next assessed
532alterations in gene expression of the other inflammasome-
Fig. 6 Antibody-directed
neutralization of S100B prevents
demyelination caused by
lysophosphatidylcholine (LPC).
Cerebellar organotypic slice
cultures were exposed to LPC at
7 days in vitro for 18 h. Double
immunostainings were performed
in slices fixed at 48 h for neuronal
axons (neurofilament-200 (NF-
200)) and mature
oligodendrocytes (myelin basic
protein (MBP)) and nuclei were
stained with DAPI (blue). a
Representative images are shown.
Scale bar represents 100 μm. b
Quantification of axon integrity
was taken by averaging the area
occupied by NF-200 staining for
each stack. c The percentage of
myelinated fibres was calculated
by the ratio between the area of
co-localization of NF-200 and
MBP and the total area occupied
by NF-200. Results are mean±
SEM from at least eight
independent experiments. One-
way ANOVAwith Tukey post-
test was used to determine the
statistical significance as
appropriate (**P<0.01 vs.
control; ##P<0.01 vs. LPC alone)
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533 related molecules. As shown in Fig. 10, LPC-induced demye-
534 lination markedly increased IL-18 (10.9-fold vs. control,
535 P<0.01), HMGB1 (14.8-fold vs. control, P<0.01) and NLRP3
536 (11.0-fold vs. control, P<0.01) gene expression. As observed
537 for cytokine profile, co-incubation of LPC-treated slices with
538 anti-S100B antibody significantly inhibited the LPC-induced
539 expression of HMGB1, IL-18 and NRLP3, in which levels
540 remained similar to control ones (P<0.01). These results clearly
541 indicate that by neutralizing S100B, we can reduce the inflam-
542 matory milieu during a demyelinating insult. Moreover, since
543 microglia are the most potent producers of inflammatory cyto-
544 kines, it is important to note that even if the number ofmicroglia
545 was not altered by S100B neutralization, their phenotype may
546 have shifted from a neurotoxic to a more neuroprotective one.
547 Discussion
548 In the present study, we show that S100B levels are signifi-
549 cantly increased in CSF and serum samples from MS patients
550 at the time of diagnosis of RRMS and that S100B expression
551is strikingly upregulated in active and chronic active lesions
552where it predominantly localized to reactive astrocytes. More-
553over, we observed an increased expression of its receptor
554RAGE in macrophages/microglia throughout active lesions.
555Using an experimental demyelinating model, we demonstrat-
556ed that demyelination induces a marked upregulation and re-
557lease of S100B protein, in parallel with astrocytosis,
558microgliosis and enhanced gene expression of key pro-
559inflammatory cytokines and NLRP3 inflammasome mole-
560cules. Therapeutic antibody-mediated neutralization of
561S100B prevented LPC-induced demyelination, reactive
562astrogliosis and cytokine and inflammasome expression. Tak-
563en together, our data indicate that S100B is a key element in
564the inflammatory process of an MS lesion and an interesting
565therapeutic target.
566Firstly, we showed that S100B levels were higher in the
567CSF and serum of MS patients at the time of diagnosis of
568RRMS when compared to control patients. Although in-
569creased CSF concentrations of S100B were already reported
570in previous studies in acute phases or during the course of the
571disease [16, 18, 30, 31], our study is the first to demonstrate
Fig. 7 S100B neutralization
prevents astrocytic morphological
activation in the course of
demyelination. Cerebellar
organotypic slice cultures were
exposed to
lysophosphatidylcholine (LPC) at
7 days in vitro for 18 h. Double
immunostainings were performed
in slices fixed at 48 h for
astrocytes (glial fibrillary acidic
protein (GFAP)) and mature
oligodendrocytes (myelin basic
protein (MBP)). Nuclei were
stained with DAPI (blue). a
Representative images are shown.
Scale bar represents 100 μm. b
Quantification of astrocytes was
taken by averaging the area
occupied by GFAP staining for
each stack. Results are mean±
SEM from at least eight
independent experiments. One-
way ANOVAwith Tukey post-
test was used to determine the
statistical significance as
appropriate (**P<0.01 vs.
control; ##P<0.01 vs. LPC alone)
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572 that also at the time of diagnosis, S100B can be viewed as an
573 initial biomarker of MS. These results are also in line with a
574 previous study from Petzold and colleagues demonstrating a
575 significant trend for increasing S100B levels from primary
576 progressive multiple sclerosis (PPMS) to secondary progres-
577 sive multiple sclerosis (SPMS) to RRMS [16], suggesting its
578 potential usefulness as a differential biomarker to distinguish
579 between the different types of MS. Additional studies should,
580 however, be performed to evaluate whether different levels of
581 S100B could be associated with differentMS stages and there-
582 fore be used as a prognostic tool. Moreover, since S100B was
583 recently reported to decrease upon MS treatment with
584 natalizumab but not with interferons, it can be also considered
585 as a biomarker for treatment efficacy. Increased levels of
586 S100Bwere similarly noticed in situations of acute brain dam-
587 age including stroke [32], rapid parenchymal destruction [33]
588 or traumatic brain injury [34]. However, this increase should
589 be distinguished from that observed in progressive diseases,
590 such as MS, where sustained S100B, as detected herein in the
591 chronic MS lesions, might have different roles by modulating
592the inflammatory response [35, 36] and consequently modify
593the disease progression by yet unknown mechanisms. Al-
594though there are other sources of S100B than the CNS, such
595as adipose tissue, testis and skin [15, 37, 38], the elevation of
596S100B in serum has been associated with blood-brain barrier
597(BBB) disruption [39], which is in line with the presence of
598signs of BBB breakdown in the very early stages of MS [40].
599Petzold and colleagues demonstrated increased levels of
600S100B in tissue homogenates of distinct lesion types [16];
601however, information on the cellular source of S100B and
602localization of RAGE in the CNS has been mainly based on
603immunohistochemical studies using rodent brain samples.
604Here, we show for the first time that astrocytes in active and
605chronic active lesions abundantly express S100B. In fact, tak-
606ing into account rodent data, astrocytes are assumed as the
607CNS cell type with the highest expression rate of S100B and
608to constitutively secrete the protein [36, 41]. Concerning
609S100B receptor RAGE expression, in NAWM the receptor
610is predominantly found in the nuclei of glial cells, suggesting
611an immature/inactive state. Mature RAGE, composed of three
Fig. 8 S100B neutralization does
not prevent microglia
proliferation/activation induced
by lysophosphatidylcholine
(LPC) demyelination. Cerebellar
organotypic slice cultures were
exposed to LPC at 7 days in vitro
for 18 h. Double
immunostainings were performed
in slices fixed at 48 h for
microglia (ionized calcium-
binding adapter molecule-1 (Iba-
1)) and mature oligodendrocytes
(myelin basic protein (MBP)).
Nuclei were stained with DAPI
(blue). a Representative images
are shown. Scale bar represents
100 μm. b Quantification of
microglia was taken by averaging
the area occupied by Iba-1
staining for each stack. Results
are mean±SEM from at least
eight independent experiments.
One-way ANOVAwith Tukey
post-test was used to determine
the statistical significance as
appropriate (**P<0.01 vs.
control)
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612 major domains, an extracellular ligand-binding domain, a sin-
613 gle transmembrane helix and a C-terminal domain [42], has to
614 form constitutivemultimers within the cytoplasmic membrane
615 to become engaged and activate downstream signalling [43,
616 44]. In accordance, nuclear expression of RAGE in NAWM
617 may represent a ubiquitous expression of RAGE under a non-
618 active form. Conversely, microglial and macrophage RAGE
619 expression was enhanced in active lesions as well as in the rim
620 of chronic active lesions, and its expression was within cell
621 soma and processes suggesting RAGE assembly to the mem-
622 brane allowing its subsequent engagement by S100B. S100B
623action through RAGE, a multiligand receptor, usually in-
624volves pro-inflammatory responses by activation of nuclear
625factor-kB, including the expression of cytokines [45] and re-
626cruitment of astrocytes [46] and microglia [47, 48] to the dam-
627aged site.
628Using LPC-induced demyelination of cerebellar
629organotypic slice cultures, we observed that a demyelinating
630insult elicits a marked astrocytic upregulation and secretion of
631S100B indicating that astrocytes are the major producers of
632S100B in the course of demyelination. In agreement with this,
633recent studies in ex vivo rat cerebellar slice cultures have
Fig. 9 S100B neutralization prevents the increase of tumour necrosis
factor (TNF-α) and interleukin (IL-1β) expression and the inhibition of
IL-6 expression induced by lysophosphatidylcholine (LPC)
demyelination. Cerebellar organotypic slice cultures were exposed to
LPC at 7 days in vitro for 18 h. Gene expression of TNF-α (a), IL-1β
(b) and IL-6 (c) was assessed at 48 h by qreal-time PCR. Results aremean
±SEM from at least eight independent experiments. One-way ANOVA
with Tukey post-test was used to determine the statistical significance as
appropriate (**P<0.01 vs. control; #P<0.05 and ##P<0.01 vs. LPC
alone)
Fig. 10 S100B neutralization prevents NLRP3 activation and
i n f l ammasome - r e l a t e d p ro t e i n exp r e s s i on i nduced by
lysophosphatidylcholine (LPC) demyelination. Cerebellar organotypic
slice cultures were exposed to LPC at 7 days in vitro for 18 h. Gene
expression of interleukin (IL-18) (a), high-mobility group box
chromosomal protein 1 (HMGB1) (b) and NRLP3 (c) was assessed at
48 h by qreal-time PCR. Results are mean±SEM from at least eight
independent experiments. One-way ANOVA with Tukey post-test was
used to determine the statistical significance as appropriate (**P<0.01
vs. control; ##P<0.01 vs. LPC alone)
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634 shown an increase in astrocyte population 2 DIV after a de-
635 myelination insult with LPC [25]. The minor co-localization
636 with OLs suggests that OLs are able to produce small amounts
637 of S100B when exposed to a toxic stimulus, as previously
638 described for an OL cell line, the OL-93, under serum and
639 glucose deprivation conditions [49]. Most striking, we ob-
640 served that sequestering excessive release of S100B signifi-
641 cantly reduced LPC-mediated myelin loss, indicating that dur-
642 ing demyelination the released S100B is promoting either di-
643 rectly or indirectly demyelination or delayed remyelination. It
644 is known that high S100B triggers microglial and astrocyte
645 activation promoting the release of nitric oxide (NO) and
646 TNF-α [12], which are deleterious for oligodendrocytes [50]
647 and may exacerbate demyelination. Curiously, our ongoing
648 studies on the role of S100B on oligodendrocyte differentia-
649 tion using primary cultures demonstrated that high S100B, at
650 the micromolar range, affects oligodendrocyte precursor cell
651 differentiation and maturation into myelinating oligodendro-
652 cytes, while low physiological S100B levels slightly enhance
653 oligodendrocyte maturation. These results suggest that during
654 remyelination S100B high levels may directly affect this pro-
655 cess possibly delaying de novo myelin formation. It deserves
656 to be noted that expression of S100B by oligodendrocyte pre-
657 cursor cells is needed for a proper differentiation into
658 myelinating oligodendrocytes [51], so by neutralizing the ex-
659 cessive S100B in the inflammatory milieu using a directed
660 antibody, we are only acting extracellularly preventing
661 S100B toxic effects. Conversely, a complete and non-
662 targeted blockade of S100B expression using silencing or
663 knock-down techniques may prove to be a deleterious ap-
664 proach affecting remyelination and damage recovery.
665 Reactive gliosis is a common pathological feature of MS
666 pathology [52]. Our results show an increase of astrocytic
667 activation upon LPC treatment evidenced by reduction of cell
668 extension length and inflated cell body. This LPC-induced
669 activation of astrocytes was shown to be diminished in the
670 presence of anti-S100B. Reactive astrocytes, which are impli-
671 cated in formation of the glial scar, are characterized by pro-
672 found morphological and genetic changes [27]. Astrocyte ac-
673 tivation has been observed during LPC-induced demyelin-
674 ation [25], and here, we show that astrocytes abundantly se-
675 crete S100B when exposed to the demyelinating agent. More-
676 over, excess of extracellular S100B levels may induce auto-
677 crine astrocytic activation that turns astrocytes into a pro-
678 inflammatory and neurodegenerative phenotype [53]. In this
679 situation, astrocytes secrete pro-inflammatory factors, which
680 are known inhibitors of OPC proliferation and maturation,
681 following demyelination in MS [54]. Thus, the apparent ab-
682 sence of astrocytosis under demyelinating conditions in the
683 presence of anti-S100B is a potential indication that high
684 levels of S100Bmight be favouring demyelination.Moreover,
685 astrocytes are involved in the production of growth factors and
686 chemokines that promote OPC activation and differentiation
687[55]. Therefore, dampening astrocyte activation by S100B
688antibody treatment may also boost remyelination.
689Microglial activation contributes to a pro-inflammatory en-
690vironment by the secretion of pro-inflammatory factors, po-
691tentiating demyelination, a feature that has also been described
692in ex vivomodels as a consequence of demyelination [25, 56].
693Accordingly, our results reveal an increase in microglial pro-
694liferation and activation in the course of demyelinating insult
695which corroborates the increase of RAGE-expressing
696microglia/macrophages observed in lesion specimens. In ad-
697dition, in parallel to increased S100B, we observed a marked
698release of first-line cytokines TNF-α and IL-1β upon demye-
699lination, which corroborates previous studies showing that
700high S100B concentrations induce microglial secretion of
701pro-inflammatory cytokines [4, 35]. On the other hand, our
702results show that neutralization of S100B does not change
703microglia number in the slice but prevents TNF-α and IL-
7041β induction, as well as IL-6 inhibition following LPC treat-
705ment. Since these cytokines are mainly expressed by activated
706microglia, their inhibition following S100B neutralization cor-
707roborates microglial shift from a pro-inflammatory phenotype
708to a more neuroprotective one. Indeed, microglia have an im-
709portant role in remyelination by clearing myelin debris [57,
71058] and switching from a cytotoxic to protector phenotype at
711remyelination initiation [59]. Moreover, once extracellular
712S100B is known to inhibit microglial activation at low con-
713centrations [4, 35], it is possible that S100B neutralization can
714prevent microglial pro-inflammatory activation upon demye-
715lination, a finding beyond the scope of this manuscript.
716Several lines of evidence suggest the involvement of
717NLRP3 inflammasome on MS development. Indeed, not only
718IL-1β [60] but also HMGB1 [61] and IL-18 [62] were found
719to be upregulated either in the serum, CSF or active lesions of
720MS patients or in rodent experimental autoimmune encepha-
721lomyelitis (EAE) lesions and associated with disease progres-
722sion [63, 64]. Also, NLRP3 has been associated with MS
723progression and it was recently reported that Nlrp3 KO mice
724are resistant to EAE [65]. Our ex vivo demyelinating model
725shows increased expression of HMGB1, IL-1β and IL-18,
726thus corroborating such findings. Most attractively, the
727marked inhibition of inflammasome-related molecules by
728neutralization of S100B shows for the first time the involve-
729ment of S100B in NLRP3 inflammasome induction upon de-
730myelination. Curiously, NLRP3 expression [66], as well as
731RAGE activation [67], was recently associated with chemo-
732tactic immune cell migration to the CNS in EAE, a hallmark
733of disease progression and damage exacerbation. So, our find-
734ings also suggest that S100B either alone or through NLRP3
735inflammasome induction may be promoting CNS immune
736cell invasion during demyelination, which may be potentially
737attenuated by S100B therapeutic neutralization as tested here.
738Taking into account the beneficial outcome of S100B inhi-
739bition in our ex vivo demyelinating model, it seems that this
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740 protein may be considered a potential therapeutic target to
741 reduce damage during MS course. S100B targeting has al-
742 ready been tested in other disease models with promising re-
743 sults. In fact, pentamidine, a S100B inhibitor, reduces S100B
744 and RAGE expression in an animal model of Alzheimer’s
745 disease, with consequent reduction of pro-inflammatory mi-
746 lieu in the hippocampus [68]. Other potential therapeutic strat-
747 egies may be the use of specific RAGE antibodies to prevent
748 S100B binding, small molecules or anti-S100B aptamers [69,
749 70]. In an indirect manner, also, induction of immune toler-
750 ance, as described for the anterior-chamber-associated im-
751 mune deviation (ACAID) method [71], by preventing myelin
752 destruction, could avoid astrocyte activation and consequent
753 S100B release.
754 Taken together, the high production of S100B at the time of
755 diagnosis of RRMS and its presence in active and chronic
756 active MS lesions suggest its interest as a potential new bio-
757 marker for MS diagnosis. Moreover, based on the beneficial
758 outcome of its inhibition in an ex vivo demyelinating model,
759 S100Bmay also be considered a potential therapeutic target to
760 reduce damage during the course of MS.
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